JUYOUNG JACKSON: Open Payments
NPI 1376019315 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,550 in 211 payments from 24 companies in 2025. Trend: 2023 $4,740 · 2024 $4,880 · 2025 $4,550
Food & beverage: $4,550
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $775 |
| PFIZER INC. | 27 | $618 |
| Novartis Pharmaceuticals Corporation | 19 | $449 |
| UCB, Inc. | 22 | $422 |
| Amgen Inc. | 23 | $404 |
| E.R. Squibb & Sons, L.L.C. | 14 | $330 |
| AstraZeneca Pharmaceuticals LP | 10 | $232 |
| GlaxoSmithKline, LLC. | 10 | $213 |
| Mallinckrodt Hospital Products Inc. | 7 | $183 |
| GENZYME CORPORATION | 5 | $137 |
Products named: RINVOQ, Bimzelx, XELJANZ, COSENTYX, SKYRIZI, ORENCIA, SAPHNELO, OCTAGAM IMMUNE GLOBULIN (HUMAN).
Industry payments across AL — which companies pay providers there.
